Fujisawa Pharmaceutical Company, Ltd.

Eiko Kino

Hirokazu Tanaka

Hiroshi Imanaka

Masanobu Kohsaka

Hatsuo Aoki

Koichi Ikushima

Akira Arakawa

Ohe Osamu

Masakuni Okuhara

Sumio Kiyoto

The invention relates to a pharmaceutical composition for treating lymphocytic leukemia, melanoma or mammary carcinoma comprising an effective amount of FR-900216.

Antitumor agent comprising FR-900216

1,4-naphthoquinone derivatives represented by the following general formula: ##STR1## (wherein R.sup.1 represents a hydrogen atom, a hydroxy group, a lower alkoxy group or an arylthio group, R.sup.2 represents a carboxy group, an esterified carboxy group or an amidated carboxy group or, when taken together, R.sup.1 and R.sup.2 form a group of ##STR2## R.sup.3 represents a hydrogen atom or a lower alkyl group, R.sup.4 represents a lower alkyl group, R.sup.5 represents a hydrogen atom or a halogen atom, and R.sup.6 represents a hydrogen atom, a lower alkyl group or a lower alkanoyl group), and the salts of the carboxy group thereof, which are novel compounds having an anticoccidium activity, and which can be obtained by synthesis or, partly, by cultivation of Streptomyces auranticolor.

1,4-Napthoquinone derivatives and use thereof

1,4-Naphtoquinone derivatives and their use in treating coccidiosis

Growing community of inventors

Hadano, Japan

Eiko Kino